Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
*The ASD comprises of 10 asthma symptoms and activity terms: 5 items in the morning and 5 items in the evening. ASD ranges from 0 (no symptoms) to 4 (worst possible symptoms). The score is the mean of the 10 items1,2
†Eosinophilic and non-eosinophilic, allergic and non-allergic; irrespective of biomarkers (bEOS, IgE or FeNO).
TEZSPIRE (tezepelumab) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment3
ACQ-6=asthma control questionnaire-6; AQLQ(S)+12=standardised asthma quality of life questionnaire for 12 years and older; ASD=asthma symptom diary; bEOS=blood eosinophils; CI=confidence interval; FeNO=fractional exhaled nitric oxide; IgE=immunoglobulin E; LS=least squares; PRO=patient reported outcomes.
GB-56889 | November 2024
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
